The FTSE 100 has joined major markets in bouncing higher at the start of the week.
As welcome as this morning’s moves will be to traders after what was a tough week, a healthy dose of cynicism still exists. Last week saw awful German data out on each of the last three trading days and it is hard to believe that this week’s ZEW, inflation and GDP figures will paint a picture that is any more appealing. With all of this looming, traders are enjoying the bounce but are fearful of its longevity.
Slightly mixed messages are coming out of Balfour Beatty this morning, following the announcement that pre-tax profits have collapsed by 53%. It has also confirmed it has turned down a second offer from Carillion stating that 'it saw no strategic logic for the merger other than to enhance the earnings', something it appears Balfour Beatty could do with. GlaxoSmithKline has confirmed it is about to embark on clinical trials for a new vaccine for the deadly Ebola virus. While this is welcome news, it is probably still some time away considering the regulatory hurdle still needing to be cleared.
Friday’s news that Russian military exercises have come to a conclusion on the outskirts of Ukraine, coupled with a more proactive strategy from the White House in dealing with ISIS forces in Iraq, triggered a market rally. The US corporate calendar is now looking a little bare, and sentiment is likely to be guided by a combination of economic releases and the developing global macro picture. Ahead of the open we expect the Dow Jones to start 37 points higher at 16,590.
As welcome as this morning’s moves will be to traders after what was a tough week, a healthy dose of cynicism still exists. Last week saw awful German data out on each of the last three trading days and it is hard to believe that this week’s ZEW, inflation and GDP figures will paint a picture that is any more appealing. With all of this looming, traders are enjoying the bounce but are fearful of its longevity.
Slightly mixed messages are coming out of Balfour Beatty this morning, following the announcement that pre-tax profits have collapsed by 53%. It has also confirmed it has turned down a second offer from Carillion stating that 'it saw no strategic logic for the merger other than to enhance the earnings', something it appears Balfour Beatty could do with. GlaxoSmithKline has confirmed it is about to embark on clinical trials for a new vaccine for the deadly Ebola virus. While this is welcome news, it is probably still some time away considering the regulatory hurdle still needing to be cleared.
Friday’s news that Russian military exercises have come to a conclusion on the outskirts of Ukraine, coupled with a more proactive strategy from the White House in dealing with ISIS forces in Iraq, triggered a market rally. The US corporate calendar is now looking a little bare, and sentiment is likely to be guided by a combination of economic releases and the developing global macro picture. Ahead of the open we expect the Dow Jones to start 37 points higher at 16,590.
Recommended Content
Editors’ Picks
EUR/USD retreats toward 1.0850 on modest USD recovery
EUR/USD stays under modest bearish pressure and trades in negative territory at around 1.0850 after closing modestly lower on Thursday. In the absence of macroeconomic data releases, investors will continue to pay close attention to comments from Federal Reserve officials.
GBP/USD holds above 1.2650 following earlier decline
GBP/USD edges higher after falling to a daily low below 1.2650 in the European session on Friday. The US Dollar holds its ground following the selloff seen after April inflation data and makes it difficult for the pair to extend its rebound. Fed policymakers are scheduled to speak later in the day.
Gold climbs to multi-week highs above $2,400
Gold gathered bullish momentum and touched its highest level in nearly a month above $2,400. Although the benchmark 10-year US yield holds steady at around 4.4%, the cautious market stance supports XAU/USD heading into the weekend.
Chainlink social dominance hits six-month peak as LINK extends gains
-637336005550289133_XtraSmall.jpg)
Chainlink (LINK) social dominance increased sharply on Friday, exceeding levels seen in the past six months, along with the token’s price rally that started on Wednesday.
Week ahead: Flash PMIs, UK and Japan CPIs in focus – RBNZ to hold rates
After cool US CPI, attention shifts to UK and Japanese inflation. Flash PMIs will be watched too amid signs of a rebound in Europe. Fed to stay in the spotlight as plethora of speakers, minutes on tap.